RxDoctor Payments DataLook up a doctor →

Dominick Daunno, MD

Internal Medicine · Houston, TXNPI 1881652436

Payments from drug & device makers

$11,111,166in general payments, 2019–2025

Across 189 payments — averaging $58,789 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$9.2M
  • Indivior Inc.$799K
  • Tris Pharma Inc$765K
  • Merck$152K
  • Modernatx, Inc.$84K
  • AbbVie$70K
  • plus $19K from 14 others
$1,712in research payments, 2019–2025

Across 1 payment — averaging $1712.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$2K

What the payments were for

  • Travel & lodging$1,60465%
  • Food & beverage$88235%

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,111,166 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,511
Medicare patients
86
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl41$12,397
LinzessLinaclotide21$10,883
EliquisApixaban11$7,018
MyrbetriqMirabegron11$5,461
Divalproex Sodium ErDivalproex Sodium13$2,229
Atorvastatin Calcium167$2,149
Carbamazepine12$1,777
Lactulose36$1,305
Levothyroxine Sodium88$1,065
Clindamycin Phosphate11$1,042
Levetiracetam12$1,006
Ketoconazole36$902
Alendronate Sodium32$866
Oxcarbazepine12$787
Potassium Chloride42$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$69,745$10,88321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →